Cencora, INC 10-Q quarterly reports

Cencora, Inc. announced a 5.1% revenue increase for the third quarter of fiscal year 2026, driven by robust performance in its U.S. and International Healthcare Solutions segments.

Cencora, Inc. announced its financial results for the quarter and six months ended March 31, 2026, showcasing significant revenue and gross profit increases across its U.S. and International Healthcare Solutions segments, bolstered by strategic acquisitions and robust market demand.

Cencora reports a 5.5% revenue increase in Q1 fiscal 2026, driven by U.S. Healthcare Solutions and strategic acquisitions, despite an asset impairment.

Cencora reports significant revenue and profit increases, driven by the acquisition of Retina Consultants of America and strong GLP-1 product sales, despite a notable decline in operating cash flow.

Cencora's Q2 2025 revenue increased by 10.3% year-over-year, driven by growth in the U.S. Healthcare Solutions segment and the acquisition of Retina Consultants of America (RCA).

Cencora's Q1 2025 revenue increased by 12.8% year-over-year, primarily driven by growth in the U.S. Healthcare Solutions segment.

Cencora, Inc. saw a significant revenue increase in the third quarter of 2024, primarily fueled by growth in its U.S. Healthcare Solutions segment, despite ongoing legal and restructuring expenses.

Cencora's Q2 2024 results show significant revenue growth, primarily driven by the U.S. Healthcare Solutions segment, with increased sales of GLP-1 products and specialty pharmaceuticals.

Cencora Inc. saw a significant revenue increase in the first quarter of 2024, primarily driven by growth in its U.S. Healthcare Solutions segment.